Bayer has agreed to acquire KaNDy Therapeutics, a UK clinical-stage biotech company, in a deal worth up to $900 million, in a move to grow its drug development pipeline in women’s healthcare. Through the acquisition, the German healthcare company gains access to NT-814, a non-hormonal, once-daily, oral neurokinin-1,3 receptor antagonist in developmen for the treatment […]
Lampit FDA approval : Bayer has bagged approval for its antiprotozoal medication Lampit (nifurtimox) from the US Food and Drug Administration (FDA) for the treatment of Chagas disease in pediatric patients, from newly born to less than 18 years of age, weighing at least 2.5kg. Chagas disease is an infectious tropical disease caused by Trypanosoma […]
Bayer has wrapped up its previously announced $7.6 billion sale of its animal health business division to US-based Elanco Animal Health. The transaction, which was announced in August 2019, was closed after meeting the closing conditions, which includes regulatory approvals. Following the closing of the deal, Bayer has been paid $5.17 billion in cash after […]
German pharma company Bayer and specialty chemicals company Lanxess have signed corresponding agreements with Macquarie Infrastructure and Real Assets (MIRA) to sell their stakes in Currenta, a chemical park operator, for an enterprise value of €3.5 billion. Currenta, a joint venture of Bayer and Lanxess, manages and operates infrastructure, energy supply and other essential services […]
Eli Lilly and Company, the US-based pharmaceutical giant, has finalised its $8 billion acquisition of Connecticut-based biopharmaceutical firm Loxo Oncology, a move expected to significantly enhance its oncology portfolio. The deal, initially announced in January 2019, marks a pivotal step in Lilly’s strategy to focus on precision medicines tailored for cancers driven by specific gene […]
Check out results of the late-breaking blood thinner clinical trial of Rivaroxaban, Bayer & Janssen’s oral blood thinner for deep vein thrombosis treatment.
Bayer AG and Janssen Pharmaceuticals, two giants in the pharmaceutical industry, have announced significant findings from their EINSTEIN CHOICE clinical trial, showcasing the effectiveness of Xarelto (rivaroxaban), an oral blood thinner, in substantially reducing the risk of recurrent life-threatening blood clots in vein, known as venous thromboembolism (VTE). Breakthrough in VTE Management The late-breaking study […]